P X Kong1, G W Chen, X S Wang. 1. Affiliated Hospital of Shaanxi College of TCM, Xianyang, Shaanxi 712083.
Abstract
OBJECTIVE: To investigate the clinical efficacy of Tianfoshen oral liquid (TFS) in treating moderate and advanced malignant tumors and its mechanism. METHODS: Therapeutic effect of TFS in treating 71 patients of malignant tumor was analyzed with the criteria, including quality of life, 3-year survival rate and immune function. And experimental studies of inhibitory effect on tumor clone primordial cells and tumor growth rate of TFS on human gastric tumor (MGC803) cell, human liver cancer (SMMC7721) cell and mice galactophore cancer (EMT6) cell by colony forming method and dye exclusion test respectively were also conducted. RESULTS: Clinical study showed that in the 71 cases treated, the total remission rate was 45.1%, the effective rate 71.8%, with improvement in quality of life and immune function, the 1-, 2- and 3-year survival rate being 78.5%, 38.5% and 10.8% respectively and the mean survival time 24.2 months. Experimental study showed that TFS could kill the cancer cells directly, inhibit the proliferation of single clonogenic cell, and had a broad-spectrum dose-dependent inhibitory action on various tumors with significant difference in comparing with the effects of the control (P < 0.05). CONCLUSION: TFS had obvious therapeutic effect to moderate and advanced tumors, its anti-tumor effect was related to the enhancement of immune function and tumor inhibiting or direct killing action.
OBJECTIVE: To investigate the clinical efficacy of Tianfoshen oral liquid (TFS) in treating moderate and advanced malignant tumors and its mechanism. METHODS: Therapeutic effect of TFS in treating 71 patients of malignant tumor was analyzed with the criteria, including quality of life, 3-year survival rate and immune function. And experimental studies of inhibitory effect on tumor clone primordial cells and tumor growth rate of TFS on humangastric tumor (MGC803) cell, humanliver cancer (SMMC7721) cell and micegalactophore cancer (EMT6) cell by colony forming method and dye exclusion test respectively were also conducted. RESULTS: Clinical study showed that in the 71 cases treated, the total remission rate was 45.1%, the effective rate 71.8%, with improvement in quality of life and immune function, the 1-, 2- and 3-year survival rate being 78.5%, 38.5% and 10.8% respectively and the mean survival time 24.2 months. Experimental study showed that TFS could kill the cancer cells directly, inhibit the proliferation of single clonogenic cell, and had a broad-spectrum dose-dependent inhibitory action on various tumors with significant difference in comparing with the effects of the control (P < 0.05). CONCLUSION: TFS had obvious therapeutic effect to moderate and advanced tumors, its anti-tumor effect was related to the enhancement of immune function and tumor inhibiting or direct killing action.